Research programme: casein kinase I alpha stimulants - StemSynergy Therapeutics

Drug Profile

Research programme: casein kinase I alpha stimulants - StemSynergy Therapeutics

Alternative Names: SST-024; SST-112mAb; SST-215; SSTC-104; SSTC3

Latest Information Update: 15 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator StemSynergy Therapeutics
  • Class Antineoplastics; Monoclonal antibodies; Small molecules
  • Mechanism of Action Casein kinase Ialpha stimulants; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Colorectal cancer
  • No development reported Synovial sarcoma

Most Recent Events

  • 15 Jan 2018 Preclinical trials in Cancer in USA (unspecified route)
  • 09 Jan 2018 StemSynergy signs an exclusive license agreement with Exelixis for discovery and development of casein kinase 1 alpha stimulants
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Synovial-sarcoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top